Reginicin Inc. is a biotechnology firm that seeks to advance regenerative cell therapies to restore the health of damaged tissues and organs. The company is currently paying a key role in the development of PermaDerm™ which “uses the patient’s own skin cells to generate living, tissue-engineered skin for the treatment of severe burns. A small harvested section of the patient’s own skin can be grown to graft an area one hundred times its size in as little as thirty days.”
Related Links